SoFi Technologies (SOFI) Competitors

SoFi Technologies (NASDAQ:SOFI) and Royalty Pharma (NASDAQ:RPRX) are both large-cap finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings, community ranking and media sentiment.

Is SOFI or RPRX more profitable?

Royalty Pharma has a net margin of 50.53% compared to SoFi Technologies' net margin of 8.38%. Royalty Pharma's return on equity of 24.65% beat SoFi Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SoFi Technologies	8.38%	3.71%	0.67%
Royalty Pharma	50.53%	24.65%	14.44%

Which has more volatility & risk, SOFI or RPRX?

SoFi Technologies has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.

Do institutionals and insiders believe in SOFI or RPRX?

38.4% of SoFi Technologies shares are held by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are held by institutional investors. 2.6% of SoFi Technologies shares are held by insiders. Comparatively, 18.9% of Royalty Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Which has higher earnings & valuation, SOFI or RPRX?

Royalty Pharma has higher revenue and earnings than SoFi Technologies. Royalty Pharma is trading at a lower price-to-earnings ratio than SoFi Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SoFi Technologies	$2.12B	7.50	-$300.74M	$0.10	146.71
Royalty Pharma	$2.36B	6.56	$1.13B	$1.93	13.59

Does the media favor SOFI or RPRX?

In the previous week, SoFi Technologies had 18 more articles in the media than Royalty Pharma. MarketBeat recorded 27 mentions for SoFi Technologies and 9 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.83 beat SoFi Technologies' score of 0.67 indicating that Royalty Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SoFi Technologies	11 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Royalty Pharma	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Does the MarketBeat Community believe in SOFI or RPRX?

Royalty Pharma received 271 more outperform votes than SoFi Technologies when rated by MarketBeat users. Likewise, 67.86% of users gave Royalty Pharma an outperform vote while only 37.14% of users gave SoFi Technologies an outperform vote.

Company	Underperform	Outperform
SoFi Technologies	Outperform Votes 52 37.14%	Underperform Votes 88 62.86%
Royalty Pharma	Outperform Votes 323 67.86%	Underperform Votes 153 32.14%

Do analysts rate SOFI or RPRX?

SoFi Technologies currently has a consensus price target of $9.80, indicating a potential downside of 33.20%. Royalty Pharma has a consensus price target of $41.67, indicating a potential upside of 58.91%. Given Royalty Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Royalty Pharma is more favorable than SoFi Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SoFi Technologies	2 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.09
Royalty Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Royalty Pharma beats SoFi Technologies on 14 of the 18 factors compared between the two stocks.